{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:58:18Z","timestamp":1779231498044,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ijrobp.2011.05.001","type":"journal-article","created":{"date-parts":[[2011,12,23]],"date-time":"2011-12-23T16:52:44Z","timestamp":1324659164000},"page":"927-932","source":"Crossref","is-referenced-by-count":78,"title":["High-Dose-Rate Brachytherapy as Monotherapy Delivered in Two Fractions Within One Day for Favorable\/Intermediate-Risk Prostate Cancer: Preliminary Toxicity Data"],"prefix":"10.1016","volume":"83","author":[{"given":"Michel","family":"Ghilezan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Gustason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Vito","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Fontanesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyse","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Limbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2011.05.001_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0022-5347(01)64471-9","article-title":"Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels","volume":"158","author":"Vicini","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.juro.2007.03.140","article-title":"Erectile function outcome reporting after clinically localized prostate cancer treatment","volume":"178","author":"Burnett","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/02841860500326190","article-title":"Radiation therapy for prostate cancer and erectile (dys)function: The role of imaging","volume":"44","author":"Incrocci","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.ju.0000169136.55891.21","article-title":"A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy","volume":"174","author":"Vargas","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brachy.2008.09.004","article-title":"Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy","volume":"8","author":"Ghadjar","year":"2009","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib9","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.clon.2007.01.288","article-title":"HDR monotherapy brachytherapy for localised prostate cancer","volume":"19","author":"Hoskin","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.ju.0000169136.55891.21","article-title":"A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy","volume":"174","author":"Vargas","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(00)00687-8","article-title":"High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I\/II clinical trial","volume":"48","author":"Yoshioka","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1538-4721(02)00101-0","article-title":"LDR vs. HDR brachytherapy for localized prostate cancer: The view from radiobiological models","volume":"1","author":"King","year":"2002","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(00)00687-8","article-title":"High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I\/II clinical trial","volume":"48","author":"Yoshioka","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0360-3016(00)01463-2","article-title":"Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report","volume":"49","author":"Martinez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.urology.2009.04.060","article-title":"Urinary side effects and complications after permanent prostate brachytherapy: The MD Anderson Cancer Center experience","volume":"74","author":"Anderson","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.juro.2007.08.136","article-title":"Long-term urinary sequelae following 125iodine prostate brachytherapy","volume":"179","author":"Crook","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.canrad.2009.08.144","article-title":"[Iodine 125 prostate brachytherapy: Prognostic factors for long-term urinary, digestive and sexual toxicities]","volume":"13","author":"Doyen","year":"2009","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients","volume":"73","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0360-3016(02)04600-X","article-title":"Long-term urinary quality of life after permanent prostate brachytherapy","volume":"56","author":"Merrick","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.PPO.0000260917.97290.70","article-title":"Long-term rectal function after permanent prostate brachytherapy","volume":"13","author":"Merrick","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0360-3016(00)00550-2","article-title":"Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer","volume":"47","author":"Zelefsky","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0360-3016(03)00081-6","article-title":"High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity","volume":"56","author":"Yoshioka","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2010.02.013","article-title":"Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions","volume":"80","author":"Yoshioka","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2011.05.001_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2007.11.004","article-title":"HDR prostate monotherapy: Dosimetric effects of implant deformation due to posture change between","volume":"86","author":"Seppenwoolde","year":"2008","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301611006602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301611006602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T05:26:15Z","timestamp":1561094775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301611006602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0360301611006602"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.001","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}